Comparative effectiveness of chemotherapy, rituximab, and bendamustine in Medicare beneficiaries with mantle cell lymphoma
ConclusionsFor elderly patients newly diagnosed with MCL, rituximab-based regimen and bendamustine-based regimen as first-line treatment significantly decreased 1-year mortality rates, compared with chemotherapy alone.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Epidemiology | Leukemia | Lymphoma | Medicare | Myeloma | Rituxan | Study | Treanda | Velcade